Nationwide Mirabegron Injury Lawsuit Lawyers

Patients Taking Recalled Mirabegron Extended-Release Tablets May Have Questions About Health Risks, Compensation, and Their Legal Rights

What Parker Waichman LLP Found

• A specific nationwide lot is affected. The recall concerns 25-mg mirabegron extended-release tablets, 30-count bottles, NDC 70710-1159-3, lot E408618, expiring November 30, 2026.
• The recall concerns an impurity problem. Reports identify an out-of-specification impurity result associated with the active ingredient as the reason for the recall.
• FDA classified the action as Class II. A Class II recall means exposure may cause temporary or medically reversible effects or that serious consequences are considered remote.
• Patients should not automatically stop prescription treatment. FDA advises patients with Class II recalls and potential nitrosamine impurities to speak with their physician or pharmacist about appropriate replacement or treatment instructions.
• A lawsuit requires proof of injury and causation. Patients who suffered a serious diagnosed condition will generally need evidence establishing that they received affected medication and that the exposure caused or contributed to the injury alleged.

A nationwide recall involving certain mirabegron extended-release tablets has raised concerns for patients who rely on the prescription medication to control symptoms of overactive bladder. The affected medication is a 25-milligram mirabegron extended-release tablet distributed in 30-count bottles by Zydus Pharmaceuticals (USA) Inc. Reports concerning the recall identify an out-of-specification impurity result involving the drug’s active ingredient as the reason for the action. The affected medication has been identified as lot E408618, NDC 70710-1159-3, with an expiration date of November 30, 2026.

The recall has been classified by the U.S. Food and Drug Administration as a Class II recall. That classification means use of or exposure to the affected product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is considered remote. A Class II designation should not be interpreted to mean that patients should ignore the recall. It means the FDA has evaluated the available information and assigned the recall a particular level of health risk.

Patients who discover that they have medication from the affected lot should contact their pharmacist or prescribing healthcare provider for instructions. FDA guidance concerning Class II prescription-drug recalls explains that patients generally should not simply discontinue medication unless they have been instructed to do so. Stopping a prescription medication without medical guidance can create separate health concerns, and a pharmacist may be able to provide medication from an unaffected lot or another appropriate replacement.

For people who have already taken medication from the recalled lot and later developed a significant health problem, the recall may also raise legal questions. A pharmaceutical product liability claim requires considerably more than proving that someone possessed or consumed recalled medication. An attorney must investigate whether the medication contained the reported impurity, the duration and amount of exposure, the nature of the patient’s injuries, other medical risk factors, the manufacturer’s conduct, and whether medical and scientific evidence can establish that the medication caused or contributed to the claimed injury.

What Medication Is Included in the Nationwide Mirabegron Recall?

The recall involves a specific lot of mirabegron extended-release tablets, 25 mg, rather than every mirabegron prescription sold in the United States. The affected tablets were packaged in bottles containing 30 tablets. The recalled product has been reported with the following identifying information:

• Medication: Mirabegron extended-release tablets, 25 mg.
• Package size: 30-count bottle.
• NDC: 70710-1159-3.
• Lot number:
• Expiration date: November 30, 2026.

The National Drug Code and package information correspond to a 30-tablet bottle of mirabegron extended-release tablets distributed by Zydus Pharmaceuticals (USA) Inc. DailyMed, the National Library of Medicine’s repository of FDA-submitted drug labeling, identifies NDC 70710-1159-3 as the 30-count package of the 25-mg extended-release product.

This distinction is important because a patient taking mirabegron should not automatically assume that the prescription is part of this recall. Mirabegron is available from different manufacturers, in different strengths, package sizes, and lots. The pharmacy label, original bottle, prescription records, or dispensing history can help determine which product was supplied.

Patients who no longer have the original manufacturer’s bottle may still be able to determine whether they received medication from the recalled lot. Many pharmacies dispense prescription tablets into pharmacy-labeled containers rather than giving patients the manufacturer’s bottle. The pharmacy should maintain dispensing and inventory records that may identify the manufacturer, NDC, lot information, and dates during which affected medication was distributed.

Those records can become particularly important when a patient develops a health problem and later learns that medication taken months earlier was recalled.

Why Was Mirabegron Recalled?

Reports concerning the recall state that testing produced an out-of-specification result involving an impurity associated with mirabegron. Pharmaceutical manufacturing requires tightly controlled specifications for identity, strength, purity, quality, and stability. When laboratory testing shows that a drug or an ingredient does not meet an established specification, the result can trigger additional investigation and, depending upon the circumstances, a recall.

Reporting on the recall has identified the concern as an N-nitroso mirabegron impurity, a type of nitrosamine drug substance-related impurity. Nitrosamine impurities have received substantial regulatory attention because certain compounds in this category can present potential carcinogenic concerns depending on their chemical properties, concentration, and duration of exposure.

The presence of a nitrosamine does not mean that every person who swallowed an affected tablet will develop cancer or another serious disease. The FDA explains that nitrosamine risk is tied closely to the amount and duration of exposure. Nitrosamines above acceptable intake levels over extended periods may increase cancer risk, while FDA states that exposure at or below established acceptable daily intake limits over a lifetime is not expected to increase cancer risk.

That distinction is especially important in litigation. A recall alone does not establish that a particular patient’s illness resulted from the medication. Lawyers investigating a potential drug injury claim must determine the impurity involved, the concentration present in the recalled medication, how long the patient took the affected tablets, the patient’s medical history, the timing and type of diagnosed condition, and what scientific evidence exists concerning causation.

What Are Nitrosamine Drug Impurities?

Nitrosamines are chemical compounds that can form during certain pharmaceutical manufacturing processes or while medications are stored. They can arise through reactions involving chemicals used in making active pharmaceutical ingredients, excipients, manufacturing materials, environmental conditions, or packaging. FDA has devoted considerable regulatory attention to controlling nitrosamine impurities in medications and has issued guidance directing pharmaceutical companies to evaluate their products for potential nitrosamine formation and establish controls intended to keep exposure below acceptable limits.

FDA describes two broad categories of pharmaceutical nitrosamines. Some are relatively small nitrosamine molecules that can appear in different medications. Others are nitrosamine drug substance-related impurities, commonly called NDSRIs, whose chemical structures are related to the active pharmaceutical ingredient itself.

FDA considers nitrosamine control a significant pharmaceutical quality issue because some N-nitrosamine compounds can potentially cause cancer. At the same time, the risks differ considerably between compounds and exposures. The agency therefore establishes acceptable intake limits using toxicological data, chemical structure, carcinogenic potency assessments, and other scientific methods rather than treating every detected nitrosamine as presenting an identical danger.

For a patient evaluating a possible lawsuit, the relevant question is consequently not merely whether the word “nitrosamine” appears in a recall notice. The investigation must determine what impurity was found, how much was present, how much medication the individual consumed, and whether credible scientific evidence connects that exposure with the medical condition the patient later developed.

What Does an FDA Class II Recall Mean?

The FDA places recalls into Class I, Class II, and Class III categories based upon the degree of health hazard associated with the affected product.

A Class I recall involves circumstances in which there is a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death. A Class III recall generally involves a product that is not likely to cause adverse health consequences.

A Class II recall, which applies to the affected mirabegron tablets, falls between those categories. FDA defines it as a situation in which exposure may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Consumers sometimes mistakenly interpret a Class II recall as insignificant. That is not what the classification means. The product has still been recalled because it does not meet applicable standards or presents a potential health concern. What the classification communicates is FDA’s assessment of the relative risk based on the information available when the recall is evaluated.

FDA also explains that patients taking prescription medications affected by Class II recalls generally can continue their medication unless otherwise instructed by FDA or the recalling company. Patients should speak with their physician or pharmacist because suddenly discontinuing a needed prescription can sometimes create greater immediate health problems than continuing it briefly while a replacement is arranged.

What Is Mirabegron and Why Do Patients Take It?

Mirabegron is a prescription medication commonly used for overactive bladder. It works differently from many older anticholinergic bladder medications and is designed to help relax the bladder’s detrusor muscle during the storage phase of the urinary cycle.

Patients may be prescribed mirabegron when they experience symptoms such as urinary urgency, urinary frequency, and urge urinary incontinence. These conditions can significantly interfere with sleep, employment, travel, exercise, and everyday activities.

Because mirabegron is generally taken on a continuing basis, some patients may have used the medication for extended periods before learning that a particular lot was recalled. That makes careful identification of the affected medication especially important.

Patients who believe they received recalled tablets should preserve available prescription bottles, pharmacy labels, medication inserts, receipts, electronic pharmacy records, insurance statements, and correspondence concerning the recall. Even when a bottle has been discarded, pharmacy dispensing records may help establish which product was provided and during what period.

What Should Patients Taking Recalled Mirabegron Do?

Patients should first determine whether their medication actually matches the affected product information. The strength, NDC, manufacturer, lot number, and expiration date are much more useful than simply looking at the name “mirabegron.”

If the product appears to match the recalled lot, patients should contact their pharmacy or healthcare provider and follow the instructions provided regarding replacement medication. FDA specifically advises people taking prescription medications affected by potential nitrosamine impurities not to stop medication on their own without consulting a healthcare professional.

Someone who has developed new or unexplained medical symptoms should discuss them with a physician. Medical decisions should be based on the patient’s individual condition rather than assumptions about the recall.

From a legal standpoint, patients who believe they have sustained an injury should also preserve evidence. Important materials may include the medication bottle, remaining tablets, pharmacy records, photographs of labels, medical records, laboratory reports, diagnostic imaging, pathology reports, receipts, insurance documents, and a chronological record showing when the medication was taken and when symptoms appeared.

Remaining medication can potentially become significant physical evidence. A person contemplating litigation should therefore speak with counsel before discarding evidence that may be necessary to identify the product or establish exposure.

When Could a Recalled Mirabegron Lawsuit Be Filed?

A person does not ordinarily have a successful pharmaceutical lawsuit simply because medication they took was later recalled. Product liability litigation generally requires a legally compensable injury and evidence establishing that the allegedly defective product caused or materially contributed to that injury.

Depending on the applicable state law and facts, possible claims could include defective manufacturing, negligent manufacturing or quality control, failure to provide adequate warnings, breach of warranty, negligence, or other product liability theories.

A manufacturing defect claim may become relevant when a particular batch deviates from the specifications applicable to the medication. Because this recall concerns an out-of-specification impurity result involving a particular lot, attorneys examining potential cases would likely investigate manufacturing records, laboratory results, stability testing, quality-control procedures, supplier information, corrective actions, and communications concerning when the impurity was first detected.

A failure-to-warn theory could arise if evidence eventually shows that a manufacturer possessed meaningful information concerning a health risk before adequate warnings were communicated. Pharmaceutical warning claims can be particularly complicated because state laws differ and prescription drugs frequently implicate the “learned intermediary” doctrine, under which warning obligations may focus on prescribing medical professionals rather than directly on patients.

Every claim therefore requires an individualized analysis.

What Injuries Could Lead to a Mirabegron Recall Lawsuit?

At this stage, people should avoid assuming that every medical condition occurring after taking mirabegron was caused by the recalled product. A temporal connection, meaning an illness happened after medication exposure, does not by itself establish medical causation.

Potential litigation would require evidence connecting a specific injury to the particular impurity and exposure involved. This can require review of toxicology, epidemiology, pharmacology, pathology, dose and duration information, and the patient’s medical history.

Because reports concerning the recall describe a nitrosamine-related impurity, long-term cancer risk may become one area attorneys and medical professionals examine. FDA states generally that nitrosamine impurities above acceptable exposure limits over long periods may increase cancer risk. That does not establish that the specific recalled mirabegron product caused any individual patient’s cancer, and it does not mean every patient exposed to the recalled lot faces a significant cancer risk.

A potential claimant will typically need evidence of an actual diagnosis rather than fear alone. Depending on state law, claims based solely on increased risk or medical monitoring may face substantial legal limitations. People who develop serious health conditions after documented exposure should have the facts evaluated individually.

Evidence That May Matter in a Mirabegron Product Liability Case

Drug recall litigation can become document-intensive because attorneys need to establish both product identification and causation. A patient who cannot prove that they received medication from the affected lot may face difficulty connecting the recall to an injury.

Evidence potentially relevant to an investigation includes:

• Pharmacy dispensing records identifying the manufacturer, NDC, lot, fill dates, quantities, and refill history.
• Original prescription bottles, unused tablets, packaging, photographs, and recall communications.
• Medical records documenting the reason mirabegron was prescribed and the length of treatment.
• Records showing symptoms, diagnoses, testing, hospitalization, treatment, or other claimed injuries.
• Pathology or oncology records if a patient has received a cancer diagnosis.
• Insurance and billing records documenting medical expenses and medication purchases.
• Employment and income information where an illness caused substantial lost earnings.
• Manufacturer testing, quality-control, regulatory, and recall records obtained during litigation.

A law firm investigating these cases may also retain physicians, toxicologists, pharmacologists, chemists, epidemiologists, or pharmaceutical manufacturing professionals when scientific testimony becomes necessary.

Who Could Potentially Be Responsible for Injuries From Recalled Medication?

Potential defendants depend upon the facts and the law of the state governing the claim. Pharmaceutical litigation may involve the manufacturer of the finished drug, companies responsible for the active pharmaceutical ingredient, distributors, suppliers, or other businesses involved in placing a defective product into commerce.

For this recall, reports identify Zydus Pharmaceuticals (USA) Inc. in connection with the affected mirabegron tablets. DailyMed likewise identifies Zydus Pharmaceuticals (USA) Inc. as the packager associated with NDC 70710-1159-3.

Determining responsibility requires more than identifying the company name on a bottle. Attorneys may need to determine where the medication was manufactured, who supplied the active ingredient, which company performed quality testing, when test results became available, whether deviations occurred during manufacturing or storage, and what information was communicated to FDA, healthcare providers, pharmacies, and patients.

Discovery in pharmaceutical cases can include production records, internal emails, testing protocols, stability data, adverse event reports, standard operating procedures, regulatory submissions, and company communications concerning quality problems.

What Compensation May Be Available in a Recalled Drug Lawsuit?

Compensation depends on the nature of the injury, applicable state law, and evidence establishing responsibility. Someone who merely purchased recalled medication but experienced no injury may have significantly different legal rights from a person who developed a serious medical condition that can be scientifically connected to exposure.

In an actionable pharmaceutical injury case, damages may potentially include past and future medical expenses, hospitalization costs, diagnostic testing, medication expenses, rehabilitation, lost income, reduced future earning capacity, physical pain, emotional suffering, disability, and loss of normal activities.

When a defective medication contributes to a death, eligible surviving family members or the estate may have wrongful death or survival claims. The categories of damages and individuals permitted to recover differ substantially from one state to another.

Some jurisdictions also permit punitive damages when evidence establishes particularly serious corporate misconduct, although the legal requirements are demanding and such damages are never automatic simply because a recall occurred.

Statutes of Limitation Can Make Early Investigation Important

Every state imposes deadlines governing product liability and personal injury claims. Those deadlines can differ based on where the patient lives, where the medication was purchased or consumed, when the injury occurred, when the person knew or reasonably should have known about a possible connection between the product and injury, and other circumstances.

Some states apply discovery rules. Others have statutes of repose that may impose additional restrictions regardless of when an injury was discovered. Wrongful death claims can have separate deadlines.

For that reason, someone with a serious diagnosed injury and documented exposure to recalled medication should not assume that the existence of an active FDA recall pauses the statute of limitations. It generally does not.

Prompt investigation also helps preserve prescription histories, pharmacy databases, original medication containers, medical records, and other evidence that may become difficult to obtain years later.

Mirabegron Recall Lawsuit FAQs

Can I File a Lawsuit Because I Took Recalled Mirabegron?

Taking recalled mirabegron does not automatically establish a product liability claim. A viable lawsuit generally requires an injury and evidence connecting that injury to the defective medication. An attorney would first determine whether your prescription came from lot E408618 and then examine how much medication you took, how long you took it, your medical history, your diagnosis, and the scientific evidence concerning the impurity. People with a serious diagnosed medical condition following confirmed exposure may have stronger grounds for investigation than people who took the medication but experienced no injury.

Should I Stop Taking Mirabegron If My Bottle Is Included in the Recall?

Do not abruptly discontinue prescription medication solely because you discovered a Class II recall. FDA guidance states that patients generally may continue taking Class II recalled prescription medications unless otherwise directed, because abruptly stopping some medications can itself be harmful. Contact your pharmacist or prescribing healthcare provider and explain that your medication may be from the recalled lot. They can determine whether a replacement from an unaffected lot or another treatment is appropriate.

What If My Pharmacy Put the Pills in a Different Bottle and I Cannot Find the Lot Number?

That does not necessarily prevent you from determining whether your medication was affected. Pharmacies commonly transfer medication from manufacturer containers into labeled prescription bottles. The pharmacy may have dispensing, purchasing, inventory, and lot-tracking information showing what product was supplied at the time your prescription was filled. Ask the pharmacy to preserve and provide your complete prescription history. An attorney investigating a serious injury may also seek additional records establishing the manufacturer and lot.

Does a Nitrosamine Impurity Mean I Will Develop Cancer?

No. FDA explains that potential risk depends on the particular nitrosamine, the amount of exposure, and how long exposure occurred. Nitrosamines above acceptable limits over long periods may increase cancer risk, but detection of a nitrosamine does not mean every exposed patient will develop cancer. Establishing that recalled medication caused a particular person’s cancer requires individualized medical and scientific evidence.

What Should I Save If I Think I Have a Mirabegron Recall Lawsuit?

Keep the prescription bottle, remaining tablets, pharmacy paperwork, photographs of the medication and label, receipts, refill records, insurance statements, recall notices, and relevant medical records. Write down when you started and stopped taking the medication and where each prescription was filled. Do not discard potentially affected medication that may be important evidence without first obtaining appropriate instructions. These records may help attorneys establish product identification, exposure duration, medical causation, and damages.

Nationwide Mirabegron Recall Lawsuit Attorneys at Parker Waichman LLP

A medication recall can leave patients with difficult questions that a short pharmacy notice cannot answer. You may want to know how long you were exposed, whether your prescriptions came from the affected lot, what the impurity means for your health, whether your medical condition could be connected to the recalled medication, and whether the company responsible for manufacturing or distributing the drug can be held legally accountable.

Parker Waichman LLP represents people throughout the United States in serious personal injury, defective drug, product liability, and wrongful death matters. If you took recalled mirabegron and suffered a serious injury or developed a significant medical condition, our attorneys can investigate your prescription history, obtain pharmacy and medical records, identify the affected product, evaluate possible defendants, and determine whether the facts support a product liability claim.

There is no charge to discuss a potential case. Call Parker Waichman LLP at 1-800-YOUR-LAWYER (1-800-968-7529) for a free consultation. Because statutes of limitation can restrict how long injured patients have to pursue compensation, people with potentially serious claims should have their legal rights evaluated as soon as reasonably possible.